Stage I-II
Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer
(06/05/2008)
Among men with Stage I seminoma (a type of testicular cancer), post-surgery treatment with a single dose of the chemotherapy drug carboplatin is as effective as two to three weeks of radiation therapy, and also reduces the risk of cancer in the other testicle. These results were presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO).
Surgery Earlier In Life Reduces Risk of Testicular Cancer Among Males with Undescended Testis
(05/04/2007)
According to an article recently published in the New England Journal of Medicine, surgery before the age of 13 for the treatment of undescended testis reduces the risk of testicular cancer compared with surgery later in life.
Survivors of Testicular Cancer at Increased Risk of Death from Other Causes
(04/05/2007)
According to an article recently published in the Journal of the National Cancer Institute, men who have survived testicular cancer for at least one year are at a higher risk than the general population for death from all causes, particularly infection and circulatory and digestive diseases.
Firefighters Face Increased Risk of Cancer
(11/15/2006)
According to the results of a study published in the Journal of Occupational and Environmental Medicine, firefighters have an increased risk of developing certain types of cancer.
First-Degree Relatives of Patients Diagnosed with Lung Cancer Who Never Smoked At Higher Risk of Developing Cancer
(04/03/2006)
According to results presented at the American Association for Cancer Research (AACR), first-degree relative of patients who had never smoked but had been diagnosed with lung cancer have an increased risk of developing cancer within their lifetime, particularly cancers that occur before the age of 50.
More...
Stage III
Survivors of Testicular Cancer at Increased Risk of Death from Other Causes
(04/05/2007)
According to an article recently published in the Journal of the National Cancer Institute, men who have survived testicular cancer for at least one year are at a higher risk than the general population for death from all causes, particularly infection and circulatory and digestive diseases.
Sensitivity of Cancer Cells to Heat May Explain “Lance Armstrong Effect”
(07/26/2006)
In an article published in the Journal of the American Medical Association, researchers have suggested that the responsiveness of testicular cancer cells to chemotherapy may be explained by the sensitivity of these cells to heat. If this proves to be the case, it may be possible to use heat to improve response to cancer treatment in patients with other types of cancer as well.
Survivors of Testicular Cancer May Have Increased Risk of Cardiovascular Disease
(01/19/2006)
According to a recent article published in the Journal of Clinical Oncology, men who have survived testicular cancer may be at an increased risk of developing subsequent cardiovascular (heart) disease. These individuals should undergo cardiac monitoring as part of their follow-up medical care.
Many Men Able to Father Children After Testicular Cancer Treatment
(11/10/2005)
According to a study published in the Journal of the National Cancer Institute, men treated for unilateral testicular cancer between 1980 and 1994 were often able to father children after treatment. However, the specific type of treatment influenced the probability of success.
Many Men Remain Fertile After Treatment for Testicular Cancer
(08/22/2005)
A study in the British Journal of Cancer reports that although treatment for testicular cancer may affect hormone levels and quality of life, many men are able to father a child after treatment.
More...
Recurrent
Recurrent Testicular Cancer Potentially Curable with High-dose Therapy and Stem Cell Transplant
(07/26/2007)
According to an article recently published in the New England Journal of Medicine, metastatic testicular cancer that has recurred following standard therapy can potentially be cured with high-dose therapy and an autologous stem cell transplant.
Surgery Linked with Good Outcomes for Patients with Late Relapse of Metastatic Testicular Cancer
(08/25/2006)
Patients who experience a cancer relapse more than two years after treatment for metastatic nonseminomatous testicular cancer can achieve good survival rates if the cancer relapse can be treated surgically. These results were published in the journal BJU International.
Survivors of Testicular Cancer May Have Increased Risk of Cardiovascular Disease
(01/19/2006)
According to a recent article published in the Journal of Clinical Oncology, men who have survived testicular cancer may be at an increased risk of developing subsequent cardiovascular (heart) disease. These individuals should undergo cardiac monitoring as part of their follow-up medical care.
Ifosfamide/Paclitaxel/Cisplatin Highly Effective for Recurrent Testicular Cancer
(09/22/2005)
According to results recently published in the Journal of Clinical Oncology, the chemotherapy combination of ifosfamide (Ifex®), paclitaxel (Taxol®), and cisplatin (Platinol®) appears highly effective for treatment of patients with recurrent testicular cancer.
Maintenance chemotherapy with daily oral etoposide was effective in patients receiving salvage therapy for germ cell tumors.
(02/26/2002)
Treatment of patients with metastatic testicular cancer who have failed initial chemotherapy remains unsatisfactory with the majority of patients dying of cancer. At Indiana University doctors recently evaluated daily administration of an oral chemotherapy drug, etoposide, in patients who had previously responded to salvage chemotherapy. Most patients in this study had failed 2 prior chemotherapy regimens. Thirty-four patients were treated with chemotherapy, 14 with autologous bone marrow transplantation, and 23 achieved a complete remission. Etoposide was then started and given daily for 21 days a month. Three of 11 patients who achieved a partial response subsequently had a complete response, but all 3 ultimately developed recurrent cancer. Seventeen of the 23 patients (79%) who achieved a complete response before starting etoposide remain in complete remission with a follow-up of 26-49 months. This study suggests that maintenance chemotherapy may prolong complete remissions in patients with advanced metastatic testicular cancer. Such therapy may be evaluated earlier in poor risk patients. (
Journal of Clinical Oncology, Vol 13, No 5, pp 1167-1169, 1995)
More...